Abstracts tagged "prevention"

Abstract Number: 0461 • ACR Convergence 2021
Plasmablast-derived Autoantibodies from Individuals At-risk for RA That Target RA-relevant Antigens Are Polyreactive with Arthritogenic Bacteria
Meagan Chriswell¹, Jennifer Seifert², Michelle Bloom³, Cliff Rims⁴, Marie Feser⁵, Kevin Deane⁶, Jill Norris⁷, Eddie James⁸, Jane Buckner⁹, William Robinson¹⁰, V. Michael Holers¹¹ and Kristine Kuhn¹², ¹UC Denver SOM, Denver, CO, ²University of Colorado School of Medicine, Littleton, CO, ³Stanford University, Redwood City, CA, ⁴Benaroya Research Institute, Seattle, WA, ⁵University of Colorado Denver, Aurora, CO, ⁶University of Colorado Denver, Denver, CO, ⁷Colorado School of Public Health, Aurora, CO, ⁸Benaroya Research Institute at Virginia Mason, Monroe, WA, ⁹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹⁰Stanford University, Palo Alto, CA, ¹¹University of Colorado, Denver, CO, ¹²University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Circulating autoantibodies like ACPA frequently develop years before symptoms of RA, during which the individual is at-risk for disease. Several lines of evidence suggest…
Abstract Number: 0876 • ACR Convergence 2021
Antibody Response in Patients with Systemic Lupus Erythematosus After a Two-dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results)
Emilie Stavnsbjerg Larsen¹, Anna Christine Nilsson², Ulrik Stenz Justesen¹, Anne Voss³ and Isik Somuncu Johansen⁴, ¹Odense University Hospital, Odense C, Denmark, ²Odense Universitets Hospital, Odense C, Denmark, ³Department of Rheumatology, Odense University Hospital, Odense C, Denmark, ⁴Odense University Hospital, Odense, Denmark
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) often receive immunosuppressive treatment for many years, resulting in higher risk of infections, including COVID-19, and infections may…
Abstract Number: 0957 • ACR Convergence 2021
Vitamin D and Marine n-3 Fatty Acid Supplementation and Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial
Jill Hahn¹, Nancy Cook², Erik Alexander³, Sonia Friedman³, Vadim Bubes³, Joseph Walter³, Gregory Kotler³, I-Min Lee³, JoAnn Manson³ and Karen Costenbader⁴, ¹Harvard T.H. Chan School of Public Health, Boston, MA, ²Brigham and Womens' Hospital, Boston, MA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital, Belmont, MA
Background/Purpose: In observational studies, vitamin D has been inconsistently associated with reduced risk of several autoimmune diseases, and a large randomized, controlled trial has been…
Abstract Number: 1077 • ACR Convergence 2021
Effectiveness of Non-Pharmacological Interventions to Promote Work Participation of People with Rheumatic and Musculoskeletal Diseases: A Systematic Review and Meta-Regression Analysis
Maarten Butink¹, Casper Webers², Suzanne Verstappen³, Robin Christensen⁴, Louise Falzon⁵, Johannes Bijlsma⁶, Gerd Burmester⁷ and Annelies Boonen², ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+); Department of Social Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht, Limburg, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+), Maastricht, Limburg, Netherlands, ³School of Social Sciences, The University of Manchester, Manchester, United Kingdom, ⁴Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark, ⁵Center for Personalized Health, Northwell Health, New York City, NY, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Despite improvements in the treatment of rheumatic and musculoskeletal diseases (RMDs), reduced work participation persists when compared to the general population. A Task Force…
Abstract Number: 1139 • ACR Convergence 2021
Fracture Liaison Service Outcomes at a Southern California County Hospital Highlights Need for Health System Improvements
Muntarin Karim¹, lorien ahn², Jordan Thompson¹, Christina Downey³, Lorena Salto⁴ and Karina Torralba⁵, ¹Loma Linda University, Redlands, CA, ²loma linda university medical center, Loma Linda, CA, ³Loma Linda University Medical Center, Redlands, CA, ⁴Loma Linda University Health, Loma Linda, CA, ⁵Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA
Background/Purpose: Osteoporosis causes significant morbidity and mortality in the elderly. Despite the benefits of treatment, < 25% of elderly patients who fracture receive treatment. A…
Abstract Number: 1135 • ACR Convergence 2020
Barriers to Influenza Vaccination in Patients at a Tertiary Care Rheumatology Clinic
Audra Horomanski¹, Gabriela Triant¹, Kathleen Kolstad¹, Melissa Dymock² and Janice Lin¹, ¹Division of Immunology & Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²Department of Technology and Digital Solutions, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Patients with rheumatologic conditions are at high risk of hospitalization, ICU admission, and death related to influenza infection due to their underlying diseases and…
Abstract Number: 1190 • ACR Convergence 2020
Sex Differences in Cardiovascular Disease Prevention in Patients with Rheumatoid Arthritis: World-wide Data from the SURF-RA
Elena Myasoedova¹, Cynthia Crowson², Joseph Sexton³, Silvia Rollefstad³ and Anne Grete Semb⁴, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Rheumatoid arthritis (RA) is associated with 2-fold increase in risk of cardiovascular (CV) disease. Extensive evidence from the general population suggests that control of…
Abstract Number: 1742 • ACR Convergence 2020
Patients’ and Rheumatologists’ Perceptions on Preventive Intervention in Rheumatoid Arthritis and Axial Spondyloarthritis
Laurette van Boheemen¹, Janne Bolt², Marieke ter Wee³, Henriëtte de Jong², Marleen van de Sande⁴ and Dirkjan van Schaardenburg⁵, ¹Amsterdam Rheumatology and immunology Center | Reade, Amste, Netherlands, ²Amsterdam Rheumatology and immunology Center | Amsterdam UMC, Amsterdam, Netherlands, ³Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, ⁴Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁵Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: Persons at risk of developing rheumatoid arthritis (RA) may benefit from lifestyle1 or pharmacological2 interventions aimed at primary prevention. Although less studied, the same…
Abstract Number: 1744 • ACR Convergence 2020
The STAtins to Prevent Rheumatoid Arthritis (STAPRA) Trial: Clinical Results and Subsequent Qualitative Study, a Mixed Method Evaluation
Laurette van Boheemen¹, Marieke ter Wee², Samina Turk³, Marian van Beers³, Wouter Bos³, Diane Marsman⁴, Ed Griep⁵, Mirian Starmans⁶, Calin Popa⁷, Alper van Sijl³, Bart Seppen³, Maarten Boers⁸, Mike Nurmohamed⁹ and Dirkjan van Schaardenburg⁸, ¹Amsterdam Rheumatology and immunology Center | Reade, Amste, Netherlands, ²Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands, ⁵Antonius Ziekenhuis, Sneek, Netherlands, ⁶Zuyderland MC, Heerlen, Netherlands, ⁷Radboudumc, Nijmegen, Netherlands, ⁸Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands, ⁹Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands
Background/Purpose: Persons at high risk of developing rheumatoid arthritis (RA) may benefit from a low-risk pharmacological intervention aimed at primary prevention. Previous studies demonstrated disease-modifying…
Abstract Number: 1777 • ACR Convergence 2020
Low Dose Aspirin to Prevent Pre-eclampsia in SLE Pregnancies – Counselling Helps to Realize Our Full Potential
Isabell Haase¹, Matthias Schneider¹, Ralph Brinks¹ and Rebecca Fischer-Betz¹, ¹Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany
Background/Purpose: Women with Systemic Lupus Erythematosus (SLE) face a higher risk of pre-eclampsia, especially those with additional risk factors. Low dose aspirin (LDA) is known…
Abstract Number: 1977 • ACR Convergence 2020
Delivering Fracture Prevention Through Telemedicine: A Process Evaluation
Karla Miller¹, Melissa Steffen², Aaron Seaman², Zachary Anderson¹, Janiel Green¹, Shardool Patel¹, Shylo Wardyn² and Samantha Solimeo², ¹Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ²Iowa VA Healthcare System, Iowa City, IA
Background/Purpose: Guidelines recommend osteoporosis screening using dual-energy X-ray absorptiometry (DXA) in men and women at risk for osteoporosis, but screening remains low, especially in men…
Abstract Number: 0109 • ACR Convergence 2020
Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
Eileen Rife¹, Emejuaiwe Nkechinyere² and Jose Leon de la Rocha³, ¹Louisiana State University, Metairie, LA, ²Department of Veterans Affairs, New Orleans, LA, ³Louisiana State University, Auburn, AL
Background/Purpose: Descriptive study designed to assess compliance to evidence-based practice guidelines for the prevention of Glucocorticoid-Induced Osteoporosis (GIOP).Methods: We queried the electronic database of the…
Abstract Number: 0111 • ACR Convergence 2020
Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic
Amanda Stefl¹, Shikha Singla², Jessica Michaud¹, Kama Thomas², Lisa Rein² and Mary Ellen Csuka², ¹Froedtert Hospital, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Glucocorticoids (GC) are used as a long-term treatment option for an estimated 1% of the US population. The American College of Rheumatology has maintained…
Abstract Number: 0113 • ACR Convergence 2020
Improving Glucocorticoid-Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines
Marielys Figueroa Sierra¹, Atefeh Vafa¹, Shu Cao², Yuanyuan Lu³, Helen Bateman⁴, John Carter¹, Yih Chang Lin², Raquel Cuchacovich¹, Marcos Maldonado⁴, Joanne Valeriano-Marcet¹ and Gabriela Montes-Rivera⁴, ¹University of South Florida, Tampa, FL, ²University of South Florida, Morsani College of Medicine, Tampa, FL, ³Biostatistician at Graduate Medical Education Department, Tampa, FL, ⁴James A. Haley VA, Tampa, FL
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a potentially preventable complication in those who are maintained on glucocorticoid (GC) therapy. It is imperative to identify these patients…
Abstract Number: 0310 • ACR Convergence 2020
The Prediction of Psoriatic Arthritis Tool (PRESTO) Study – Interim Report
Lihi Eder¹, Ker-Ai Lee², Vinod Chandran³, Jessica Widdifield⁴, Aaron Drucker⁵, Christopher Ritchlin⁶, Cheryl Rosen⁷, Richard Cook² and Dafna Gladman³, ¹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto - Toronto, Toronto, ON, Canada, ⁵University of Toronto, Toronto, Canada, ⁶Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: A simple, scalable tool that identifies psoriasis patients at high risk for developing PsA could improve early detection and facilitate early intervention. Our overall…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].